In addition, we previously demonstrated that the CUL4 inhibitor MLN4924, an emerging anti-cancer drug [65,66,67,68,69], also effectively promotes protein expression of leukodystrophy-related ClC-2 mutant channels [20]. Here, CLCN2 is linked to leukodystrophy.